Stockscreener 앱 받기
13.62
1.02%
-0.14
시간 외 거래:
13.77
0.15
+1.10%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Aug Catalysts: Why is REGENXBIO Inc stock going upSwing Trade & Stepwise Trade Signal Guides - baoquankhu1.vn
Street Watch: Is REGENXBIO Inc impacted by rising ratesQuarterly Portfolio Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Regenxbio Shares Retreat as Market Digests Conflicting Signals - AD HOC NEWS
REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.7%What's Next? - MarketBeat
Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA - NeurologyLive
Is REGENXBIO Inc in a long term uptrendPrice Action & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
RGNX: Pivotal data and regulatory milestones in Duchenne, wet AMD, and Hunter programs drive a transformative year - TradingView — Track All Markets
RGNX: Late-stage gene therapy programs show strong efficacy, safety, and commercial readiness for 2024 - TradingView — Track All Markets
$191.2 Million Achromatopsia Market Outlook, 2026-2032, - GlobeNewswire
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Is REGENXBIO Inc stock undervalued right nowJuly 2025 Highlights & Technical Pattern Based Buy Signals - baoquankhu1.vn
Technical Reactions to RGNX Trends in Macro Strategies - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Sets New 12-Month HighHere's Why - MarketBeat
Macular Degeneration Treatment Market is expected to reach US$ - openPR.com
Hedge Fund Moves: What hedge fund activity signals for REGENXBIO Inc. stockMarket Sentiment Review & Fast Exit and Entry Trade Guides - Bộ Nội Vụ
Market Overview: Is REGENXBIO Inc stock undervalued right now2025 Price Action Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Lobbying Update: $60,000 of REGENXBIO INC. lobbying was just disclosed - Quiver Quantitative
REGENXBIO (NASDAQ:RGNX) Shares Gap UpShould You Buy? - MarketBeat
Regenxbio (RGNX) Shares Rise on Promising Duchenne Therapy Data - GuruFocus
Regenxbio stock maintains Buy rating at H.C. Wainwright on positive DMD trial data - Investing.com Australia
REGENXBIO Stock Hits New High On Duchenne Trial DataWill 2026 Be A Transformative Year? - RTTNews
Regenxbio stock rating reiterated at Outperform by Baird on positive RGX-202 data - Investing.com Australia
REGENXBIO (RGNX) Advances Gene Therapy Pipeline for Future Miles - GuruFocus
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - Chartmill
Aug PostEarnings: How REGENXBIO Inc stock performs during Fed tightening cycles2025 Major Catalysts & Smart Investment Allocation Tips - moha.gov.vn
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 107% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Why REGENXBIO Inc. stock is trending among retail traders2025 Volume Leaders & Safe Capital Growth Stock Tips - Улправда
What hedge fund activity signals for REGENXBIO Inc. stockMarket Performance Report & Safe Swing Trade Setup Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsPortfolio Gains Report & Growth Focused Entry Reports - ulpravda.ru
How REGENXBIO Inc. stock trades during market volatilityJuly 2025 Levels & Daily Chart Pattern Signal Reports - Улправда
Is REGENXBIO Inc. stock gaining market share2025 Institutional Moves & Low Risk High Reward Ideas - ulpravda.ru
How REGENXBIO Inc. stock benefits from global expansionDividend Stock Watch & Start Your Free Trading Journey Today - ulpravda.ru
REGENXBIO (NASDAQ:RGNX) Sets New 1-Year HighStill a Buy? - MarketBeat
RegenXBio (RGNX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Raises Price Target on REGENXBIO to $28 From $20, Maintains Buy Rating - marketscreener.com
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy - MSN
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
Regenxbio (RGNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Squarepoint Ops LLC Boosts Holdings in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. stock reach Wall Street targetsForecast Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is REGENXBIO Inc. stock a smart buy before Fed meetingJuly 2025 Trends & Scalable Portfolio Growth Ideas - ulpravda.ru
4.73%
0.92%
자본화:
|
볼륨(24시간):